Compare DAIO & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAIO | CRIS |
|---|---|---|
| Founded | 1969 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.9M | 20.6M |
| IPO Year | 1995 | 2000 |
| Metric | DAIO | CRIS |
|---|---|---|
| Price | $3.92 | $0.37 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $5.22 | ★ $17.00 |
| AVG Volume (30 Days) | 144.5K | ★ 446.3K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.57 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $21,500,000.00 | $9,898,000.00 |
| Revenue This Year | $4.51 | $27.10 |
| Revenue Next Year | $30.29 | $67.74 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 31.50 |
| 52 Week Low | $2.16 | $0.38 |
| 52 Week High | $4.49 | $2.48 |
| Indicator | DAIO | CRIS |
|---|---|---|
| Relative Strength Index (RSI) | 59.81 | 31.80 |
| Support Level | $2.89 | N/A |
| Resistance Level | $4.10 | $0.57 |
| Average True Range (ATR) | 0.28 | 0.05 |
| MACD | -0.05 | -0.00 |
| Stochastic Oscillator | 68.91 | 3.16 |
Data I/O Corp provides semiconductor programming, security provisioning, and intellectual property protection and management solutions used in electronics manufacturing with flash memory, microcontrollers, and flash memory-based intelligent devices as well as secure element devices, authentication devices and secure microcontrollers. It operates as a single segment entity, with the sole objective to design, manufacture, and sell programming solutions and Programming-as-a-Service (PaaS) to the world's various electronics manufacturers including OEMs, CMs and EMS companies. The company operate in three separate locations Redmond, Washington; Shanghai, China; and Munich, Germany.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.